Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
The University of Texas MD Anderson Cancer Center · Westmead Hospital · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
933
total citations
- FWCI
- 58.59
- Percentile
- 100%
- References
- 32
Citations per year
Authors
17- GSGerald S. FalchookCorresponding
The University of Texas MD Anderson Cancer Center
- GVGeorgina V. Long
Westmead Hospital, The University of Sydney, Melanoma Institute Australia, Westmead Institute
- RKRazelle Kurzrock
The University of Texas MD Anderson Cancer Center
- KBKevin B. Kim
The University of Texas MD Anderson Cancer Center
- TATobias Arkenau
GlaxoSmithKline (Australia), Prince of Wales Hospital
Topics & keywords
Topics
Keywords
- Dabrafenib
- Medicine
- Melanoma
- Tolerability
- Adverse effect
- Response Evaluation Criteria in Solid Tumors
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.